ππ‘ New and interesting player on the pharmaceutical market! ππ
One of the most discussed topics in the pharmaceutical market is the treatment of obesity and diabetes. Only two companies are behind many successful drugs such asOzempic, Rybelsus and Saxenda: Novo Nordisk $NVO and Eli Lilly $LLY. These companies have had significant success in the treatment of diabetes and obesity with innovative agents such as semaglutide and tirzepatide.
However, a new player has now arrived on the scene , Viking Therapeutics $VKTX, and it could change the game. This biotech company is about to enter the fray with the well-known giants. With positive results from clinical trials for its VK2735, combining GLP-1 and GIP receptors, the company has seen its stock price soar.
There are currently two opportunities for the company. Thefirst option is to move quickly into Phase 3 trials and work with the FDA to bring the drug to market. The second option is a more interesting scenario in the form of anacquisition. Pfizer $PFE could be a potential suitor. Although Pfizer recently dove into the complicated Seagen acquisition and faces financial challenges, a potential acquisition of Viking could provide a boost to its existing portfolio.
What is your favorite pharmaceutical company?π
For me, it's $PFEa $LLY.
$MRNA has made little profit so far, but the expected results of studies this year give a decent chance for much more growth.